The FDA has approved Suzetrigine (Journavx), a novel non-opioid pain medication, which could offer a significant alternative to opioids for managing acute pain. Dr. Cheng, a leading expert in pain management, highlights the potential of this medication to address the widespread issue of opioid dependence while providing effective pain relief for millions of patients.
The Food and Drug Administration (FDA) is hopeful that a newly approved non-opioid pain medication could help save lives. 'Eighty million people suffer from acute pain, whether from surgery, trauma, or other injuries, and the current mainstream treatment is opioids,' said Dr. Cheng. It's called Suzetrigine , also known as Journavx . He said it targets a pain-signaling pathway in the peripheral nervous system.
It works in a similar way to how an anti-depressant or anti-seizure medication works in the central nervous system. 'This is something in-between that can be applicable for a large number of patients,' said Dr. Cheng. Although this wouldn't stop the use of opioids altogether, he said it's a strong alternative when appropriate. 'Maybe not as good as a strong opioid, but it does bridge the gap between no opioid, a weak opioid, and strong opioids,' he said
Non-Opioid Pain Medication Suzetrigine Journavx FDA Approval Opioid Alternative
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Vertex's Non-Opioid Painkiller: A New Era in Pain ManagementThe Food and Drug Administration (FDA) has greenlit Vertex Pharmaceutical's non-opioid painkiller, presenting a groundbreaking alternative to traditional opioid-based pain relief options and offering hope in the fight against the opioid epidemic.
Read more »
FDA Approves Vertex's Non-Opioid Painkiller Journavx, Offering Hope for Millions Suffering from PainVertex Pharmaceuticals' non-opioid painkiller, Journavx, receives FDA approval, marking a significant milestone in the fight against the opioid epidemic. The drug offers a safe and effective alternative for pain relief without the risk of addiction.
Read more »
FDA Approves Vertex Pharmaceuticals' Non-Opioid Painkiller JournavxThe Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals' non-opioid painkiller, Journavx, marking a significant step forward in safer pain management. This milestone comes after years of efforts to develop alternatives to addictive opioids. Journavx works by blocking pain signals at their source, unlike opioids which directly impact the brain.
Read more »
FDA Approves First Non-Opioid Painkiller for Moderate to Severe Acute Pain in Over 20 YearsJournavx (suzetrigine), a revolutionary non-opioid painkiller, has received FDA approval, offering a much-needed alternative to addictive opioids for managing moderate to severe acute pain. Clinical trials demonstrate its effectiveness and rapid pain relief, exceeding the benefits of placebo.
Read more »
FDA Approves First Non-Opioid Painkiller for Moderate to Severe Acute PainThe Food and Drug Administration (FDA) has approved Journavx, a new non-opioid painkiller developed by Vertex Pharmaceuticals, for the treatment of moderate to severe acute pain in adults. Experts believe this drug could reduce opioid prescriptions and provide an alternative for patients who cannot tolerate other pain medications. While clinical trials showed promising results in pain reduction after surgery, more research is needed to fully understand its long-term effects and cost-effectiveness.
Read more »
FDA Approves First Non-Opioid Pain Drug in Over 20 YearsThe FDA has approved Journavx, a new pain drug developed by Vertex Pharmaceuticals, offering an alternative to opioids and over-the-counter medications. While studies show modest effectiveness compared to opioids, the drug's unique mechanism of action targets pain signals before they reach the brain, eliminating the risk of addiction and overdose. Vertex plans to continue research on the drug for chronic pain, despite recent setbacks in a study for lower back and leg pain.
Read more »